Overview

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

Status:
Not yet recruiting

Trial end date:
2022-12-29

Target enrollment:

Participant gender:

Summary

CLARITY 2.0 is an investigator-initiated trial that will evaluate the safety and efficacy of dual treatment with repagermanium, a CCR2 antagonist, and candesartan, an ARB, in patients hospitalised with COVID-19 disease.

Phase:

Phase 2

Details

Lead Sponsor:

University of Sydney

Collaborator:

The George Institute for Global Health, India

Treatments:

Candesartan
Candesartan cilexetil
Proxigermanium